Alzinova AB (OSTO:ALZ) EBIT: kr-24.54 Mil (TTM As of Mar. 2026)


OSTO:ALZ Alzinova AB OSTO:ALZ
21 GF Score
Price kr0.55
! 1 Warning Sign
View Full Analysis

What is Alzinova AB EBIT?

Alzinova AB OSTO:ALZ +0.55% 21 EBIT is kr-24.54 Mil as of Mar. 2026. GuruFocus rates OSTO:ALZ with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

Alzinova AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was kr-4.90 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-24.54 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Alzinova AB's annualized ROC % for the quarter that ended in Mar. 2026 was -12.77%. Alzinova AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Alzinova AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -22.12%.

Alzinova AB  (OSTO:ALZ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Alzinova AB's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-19.744 * ( 1 - 0% )/( (158.316 + 151.013)/ 2 )
=-19.744/154.6645
=-12.77 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=143.431 - 2.709 - ( 0.319 - max(0, 19.807 - 2.213+0.319))
=158.316

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=158.624 - 4.23 - ( 11.381 - max(0, 9.113 - 12.494+11.381))
=151.013

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Alzinova AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-19.592/( ( (0 + max(-19.449, 0)) + (0 + max(-8.83, 0)) )/ 2 )
=-19.592/( ( 0 + 0 )/ 2 )
=-19.592/0
= %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.358) - (2.709 + 0 + 17.098)
=-19.449

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.283) - (4.23 + 0 + 4.883)
=-8.83

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Alzinova AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-24.535/110.920
=-22.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzinova AB EBIT Related Terms

Alzinova AB EBIT Historical Data

* Premium members only.

The historical data trend for Alzinova AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzinova AB EBIT Chart

Alzinova AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.52 -13.07 -16.38 -20.32 -25.33

Alzinova AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.64 -7.55 -6.93 -5.16 -4.90

OSTO:ALZ vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Alzinova AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alzinova AB EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzinova AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alzinova AB's EV-to-EBIT falls into.


OSTO:ALZ
21GF Score
Alzinova AB OSTO:ALZ
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alzinova AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-24.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr-24.54 Mil mean?
Alzinova AB (OSTO:ALZ) has a EBIT of kr-24.54 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Alzinova AB.
Is Alzinova AB's EBIT too high?
Alzinova AB's current EBIT is kr-24.54 Mil. Overall, Alzinova AB has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Alzinova AB's EBIT compare to VRTX and REGN?
Alzinova AB's EBIT of kr-24.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Alzinova AB. Alzinova AB's current EBIT is kr-24.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzinova AB stock overvalued right now?
Alzinova AB (OSTO:ALZ) has a current EBIT of kr-24.54 Mil. The current EBIT is kr-24.54 Mil. Alzinova AB's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Alzinova AB (OSTO:ALZ), the current EBIT is kr-24.54 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alzinova AB Business Description

Other Exchanges 78D:Germany
Address Entreprenorsstraket 10, Molndal, SWE, 431 53
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is developing ALZ-101, an oligomer-specific therapeutic vaccine currently advancing toward Phase 2 clinical development, and ALZ-201, a monoclonal antibody targeting toxic amyloid-beta (AB) oligomers, which is in preclinical development. The company's proprietary ABCC peptide technology is focused on disease-modifying treatments for Alzheimer's disease.
21GF Score

Get the complete analysis for OSTO:ALZ

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.55
Price